# Avalo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/avalo-therapeutics

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.avalotx.com/
- Total disclosed funding: $16M
- Latest round: Series B (Jul 18, 2014)
- Investors on record: 4

## About

Based in Maryland, US, and founded in 2011, Cerecor, Inc. operates as a biopharmaceutical company that develops drugs for the treatment of cancer, autoimmune diseases, and rare genetic disorders. In June 2021, Cerecor, Inc. raised USD 20 million in venture debt financing led by Horizon Technology Finance. As of 2021, the company is led by its CEO Michael Cola. 

The clinical-stage biotechnology firm focuses on the treatment of immune dysregulation by developing therapies. The firm is targeting the LIGHT signaling network. LIGHT is an immunoregulatory cytokine.

As of 2022, the firm is having two core programs for immune Dysregulation disorders in the pipeline which are AVTX-002 and AVTX-008. Another program named AVTX-803 is in pipeline with the mechanism of action of fucose replacement.

## Funding rounds

- Series B, Jul 18, 2014, $16M — New Enterprise Associates, Apple Tree Partners, MPM BioImpact, Hercules Capital

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B
- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B
- Hercules Capital (https://capitalatlas.ai/funds/hercules-capital) — Series B